Tenaya Therapeutics Statistics
Total Valuation
TNYA has a market cap or net worth of $185.91 million. The enterprise value is $141.13 million.
Important Dates
The last earnings date was Wednesday, March 11, 2026, after market close.
| Earnings Date | Mar 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TNYA has 216.51 million shares outstanding. The number of shares has increased by 59.81% in one year.
| Current Share Class | 216.51M |
| Shares Outstanding | 216.51M |
| Shares Change (YoY) | +59.81% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 27.43% |
| Float | 166.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.77 |
| P/TBV Ratio | 2.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.64, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.64 |
| Quick Ratio | 4.26 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -96.44% and return on invested capital (ROIC) is -54.85%.
| Return on Equity (ROE) | -96.44% |
| Return on Assets (ROA) | -49.48% |
| Return on Invested Capital (ROIC) | -54.85% |
| Return on Capital Employed (ROCE) | -105.93% |
| Weighted Average Cost of Capital (WACC) | 20.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$971,732 |
| Employee Count | 97 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +69.80% in the last 52 weeks. The beta is 3.22, so TNYA's price volatility has been higher than the market average.
| Beta (5Y) | 3.22 |
| 52-Week Price Change | +69.80% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 1.00 |
| Relative Strength Index (RSI) | 59.67 |
| Average Volume (20 Days) | 6,262,069 |
Short Selling Information
The latest short interest is 23.55 million, so 10.88% of the outstanding shares have been sold short.
| Short Interest | 23.55M |
| Short Previous Month | 25.72M |
| Short % of Shares Out | 10.88% |
| Short % of Float | 14.16% |
| Short Ratio (days to cover) | 6.46 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -97.21M |
| Pretax Income | -94.26M |
| Net Income | -94.26M |
| EBITDA | -88.51M |
| EBIT | -97.21M |
| Earnings Per Share (EPS) | -$0.72 |
Full Income Statement Balance Sheet
The company has $56.31 million in cash and $11.53 million in debt, with a net cash position of $44.79 million or $0.21 per share.
| Cash & Cash Equivalents | 56.31M |
| Total Debt | 11.53M |
| Net Cash | 44.79M |
| Net Cash Per Share | $0.21 |
| Equity (Book Value) | 82.87M |
| Book Value Per Share | 0.51 |
| Working Capital | 48.03M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$72.71 million and capital expenditures -$755,000, giving a free cash flow of -$73.47 million.
| Operating Cash Flow | -72.71M |
| Capital Expenditures | -755,000 |
| Free Cash Flow | -73.47M |
| FCF Per Share | -$0.34 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TNYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -59.81% |
| Shareholder Yield | -59.81% |
| Earnings Yield | -50.70% |
| FCF Yield | -39.52% |
Analyst Forecast
The average price target for TNYA is $5.25, which is 511.39% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.25 |
| Price Target Difference | 511.39% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |